Pharma

Two businesses under one roof

Almost every big Indian pharma company runs two businesses that could not be more different. One is the India business, where it sells branded medicines for ongoing conditions, calm, profitable and dependable. The other is the export business, mostly to the United States, where it sells plain copies of drugs whose patents have expired, in a market that grinds prices down every year. Understanding a pharma company means never mixing these two up, because they behave in completely opposite ways.

What a generic actually is

When a new drug is invented, the company that made it gets a patent, a period of years where only it can sell that drug, at a high price. Once the patent runs out, anyone who can prove they make the same molecule safely is allowed to sell their own version. That copy is called a generic. Making generics is what most Indian pharma does best. The molecule is the same as the original; the only thing that has vanished is the monopoly and the fat price that came with it.

In India, even generics carry a brand

Here is the quirk that makes the India business so good. Even though these are generic medicines, Indian companies sell them under their own brand names, and doctors get comfortable prescribing a particular brand they trust. That trust is sticky. A doctor who has prescribed a company's thyroid brand for a decade does not casually switch. So the India business earns healthy margins and enjoys a loyalty that a plain price-driven generic never could.

Chronic beats acute

Within the India business, the best kind of medicine is one for a long-term illness, what the industry calls chronic conditions: heart disease, diabetes, blood pressure, thyroid. A patient takes these every day, for years, so the prescription repeats month after month like a subscription. Medicines for short-term problems, the acute ones like a fever or an infection, are taken once and stop, so that revenue is lumpier and more seasonal. A company weighted toward chronic care has smoother, more predictable earnings.

Prices only fall

Selling generics in America is a volume game with no loyalty. Whoever offers the drug cheapest tends to win the order, and as more makers pile onto a molecule, the price only ever grinds downward. This is called price erosion, and it is relentless. A drug that earned good money this year will earn less next year purely because more competitors showed up. So the US business is a treadmill: a company has to keep launching new generics just to stand still.

Every new generic needs a permission slip (ANDA)

To sell a generic in America, a company must file an application with the US regulator proving its copy is as good as the original, and wait for approval. That filing is called an ANDA. A company's stack of pending and approved ANDAs is basically its pipeline of future US products, so a thick pipeline means years of new launches to fight the price erosion, and a thin one means trouble ahead.

The occasional jackpot: first-to-file

Once in a while there is a real prize. The first company to challenge a patent and file to make a particular generic can win six months where it is the only generic version allowed, before the crowd is let in. For those six months it enjoys near-monopoly pricing and the profits can be enormous. But it is a one-off windfall, not a steady stream, so it is important not to mistake a jackpot quarter for the normal run rate.

The American regulator inspects Indian factories

To sell medicine in America, a company's factory has to pass inspection by the US Food and Drug Administration, the USFDA, even though the plant sits in India. These inspectors turn up and check that everything is spotlessly, provably up to standard. What they find decides whether that factory can keep exporting to its most profitable market. This single relationship hangs over every Indian pharma company like weather.

The escalating ladder of trouble

When inspectors are unhappy, the trouble comes in steps. First they issue a list of observations, known as a Form 483, a warning to fix things. If it is not fixed well enough, that becomes a Warning Letter, which is serious. At the worst end sits an import alert, where America simply bans that factory's medicines until the mess is cleaned up, which can take years. Each step up the ladder chops away more of the company's most valuable revenue.

Why a great quarter can still be a landmine

This is what makes pharma unusual. A company can be growing beautifully, with a rich pipeline and rising profits, and then a single bad inspection at one important factory can wipe out a large slice of earnings overnight, no matter how well the rest of the business is doing. So with pharma you can never look only at the growth. You always have to ask how clean the factories are.

R&D is buying tomorrow's pipeline

Research and development spending is how a pharma company funds its future products. Too little, and the pipeline dries up and erosion slowly eats the business. But the kind of R&D matters as much as the amount. Spending to churn out yet more simple generics is low-value, because everyone can do it. Spending to crack hard-to-make complex generics and biosimilars, copies of advanced biological drugs, is where the durable, better-protected profits of the future live.

Leaning on one or two big drugs

Some companies earn a huge share of their US profit from just a couple of products. That is lovely while it lasts, but the moment competition arrives on one of those drugs, or its exclusivity ends, a big lump of profit can vanish at once. A pharma company resting on a couple of blockbusters is more fragile than its smooth numbers suggest.

The government capping prices at home

In India, the government keeps a list of essential medicines whose prices it controls, to keep healthcare affordable. That is good for patients, but it caps the margin on any drug that lands on the list. A company heavy in price-controlled medicines has less room to raise prices and protect its profitability.

Betting the whole business on America

A company that sells almost entirely into the US carries all the price erosion and all the factory risk in one basket. The steadier players spread their exports across America, Europe, emerging markets and a strong India business, so that a bad patch in any one place does not sink the whole ship. Geographic concentration is a quiet but real risk.

Split the calm from the lumpy

A pharma company's headline profit blends the steady India business with the jumpy, erosion-prone US business, and sometimes a one-off first-to-file windfall on top. Judge the whole thing on a single number and you can badly misread it, mistaking a lucky jackpot quarter for the normal run rate, or a temporary US slump for a broken company. The right way is to value the durable India engine for its steadiness and treat the US business for what it is: valuable, but volatile and always shadowed by factory risk.

What to actually look at

So put the single PE aside and read a pharma company through a few clearer windows.

• Domestic chronic growthHow fast the India business, especially the recurring chronic-illness brands, is growing. This is the calm, high-quality engine, and steady growth here is worth a lot.
• Pipeline quality, not just sizeNot merely how many US approvals are pending, but whether they are hard-to-make complex products that resist erosion, or ordinary generics that will be competed away. Quality of pipeline beats quantity.
• Factory track recordThe regulatory history of the key plants. A clean inspection record is worth real money; a plant under a Warning Letter is a live risk sitting under the earnings, however good the pipeline looks.
• EV/EBITDAA price gauge that handles the debt and the heavy investment better than plain PE, and lets you compare pharma companies more fairly.

Read together, these tell you how much of the profit is durable, how protected the future is, and how big the hidden factory risk is, which is far more than any single PE number can say.